Atea Pharmaceuticals, Inc.
Atea Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing oral antiviral therapies to address unmet medical needs in viral diseases, including hepatitis C and COVID-19. The company leverages its expertise in antiviral drug development, medicinal chemistry, biology, biochemistry, and virology to create innovative treatments with the potential to transform patient care.
Industries
Nr. of Employees
medium (51-250)
Atea Pharmaceuticals, Inc.
225 Franklin Street, Suite 2100, Boston, MA 02110
Patents
β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment
US-12084473-B2
View Details
β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment
US-12084473-B2
View DetailsProducts
Oral combination regimen of a nucleotide analog polymerase inhibitor and an NS5A inhibitor for hepatitis C
An oral two-drug regimen combining a nucleotide analog polymerase inhibitor and an NS5A inhibitor designed as a pan-genotypic, once-daily treatment for hepatitis C virus (HCV); demonstrated high sustained virologic response in Phase 2 and advanced to global Phase 3 development.
Oral combination regimen of a nucleotide analog polymerase inhibitor and an NS5A inhibitor for hepatitis C
An oral two-drug regimen combining a nucleotide analog polymerase inhibitor and an NS5A inhibitor designed as a pan-genotypic, once-daily treatment for hepatitis C virus (HCV); demonstrated high sustained virologic response in Phase 2 and advanced to global Phase 3 development.
Services
End-to-end internal capabilities for discovering, optimizing and advancing oral small-molecule antivirals, including medicinal chemistry, preclinical studies, CMC and clinical development.
Strategic collaborations and licensing arrangements to develop, distribute and commercialize investigational antiviral therapies.
End-to-end internal capabilities for discovering, optimizing and advancing oral small-molecule antivirals, including medicinal chemistry, preclinical studies, CMC and clinical development.
Strategic collaborations and licensing arrangements to develop, distribute and commercialize investigational antiviral therapies.
Expertise Areas
- Clinical trial management (Phase 1–3)
- Antiviral drug discovery and development
- Medicinal chemistry of nucleoside/nucleotide prodrugs
- Purine nucleotide prodrug development
Key Technologies
- Purine nucleotide prodrug chemistry
- Nucleoside/nucleotide analogs
- Viral RNA-dependent RNA polymerase inhibition
- In vitro replicon assays
News & Updates
Update on financial results and business progress, including ongoing clinical trials and collaborations.
Full results from a Phase 2 study demonstrating 98% SVR12 rate after 8 weeks of treatment with bemnifosbuvir and ruzasvir.
Panel discussion on current challenges in HCV treatment and the potential of Atea's therapies.
Partnership to develop and commercialize AT-527, an antiviral candidate, for COVID-19 treatment.
Appointment of industry veteran to the company's board to support development of antiviral therapies.
New appointments to leadership team to support late-stage development of antiviral candidates.
Update on financial results and business progress, including ongoing clinical trials and collaborations.
Full results from a Phase 2 study demonstrating 98% SVR12 rate after 8 weeks of treatment with bemnifosbuvir and ruzasvir.
Panel discussion on current challenges in HCV treatment and the potential of Atea's therapies.
Partnership to develop and commercialize AT-527, an antiviral candidate, for COVID-19 treatment.
Appointment of industry veteran to the company's board to support development of antiviral therapies.
New appointments to leadership team to support late-stage development of antiviral candidates.